Corvus Invests $5M in Angel Pharma's $13.5M Financing for Soquelitinib

Corvus Pharmaceuticals announced a $5 million investment in a new $13.5 million financing round for its Chinese collaboration partner, Angel Pharmaceuticals. This funding will support Angel Pharma's ongoing Phase 1b/2 trial of soquelitinib for atopic dermatitis and a new Phase 2 trial for asthma. Corvus, as Angel Pharma's largest shareholder, expects to benefit from the clinical data generated and its significant ownership position in the growing Chinese inflammation and immunology markets. Angel Pharma anticipates reporting initial atopic dermatitis trial results in late 2026 and starting the asthma trial in early 2027.